--> maybe why we had a rumor last week of Icahn building a stake in BMY, will be a very good news as Gilead got some delays on its Hepatitis C Drug.
Bristol-Myers Squibb Co To Present Data for Daclatasvir in Multiple Investigational All-oral Combinations across Hepatitis C Genotypes at The International Liver CongressTM
- announced today that 12 abstracts have been accepted for presentation at The International Liver CongressTM, the 49th annual meeting of the European Association for the Study of the Liver (EASL), in London, April 9 13.